The facts
Previous guidance was US$49–50 billion in revenue and adjusted earnings of US$6.75–7.00 a share. [1][2]
The revised earnings outlook includes a US$0.60-per-share impact associated with acquired in-process research and development and licensing. Adjusted earnings are a non-GAAP measure. [1][2]
Third-quarter revenue rose 7% to about US$13.1 billion, while adjusted quarterly earnings were US$1.35 a share, Reuters reported. [2]
Sales of newer medicines grew 12% from a year earlier. Reuters reported that older products’ combined sales grew 1%, including a 25% increase for Eliquis. [2]
Sources
References support the numbered facts above. Source checks: 29 Oct 2026, 13:55 UTC.
Direct filing and issuer-release access was unavailable in the checked endpoints. Two independently owned current financial reports agree on the material guidance change; non-GAAP measures and the charge retain their stated basis.
- Bristol-Myers Squibb slashes FY26 EPS outlook, but raises revenue forecast
RTTNews · Reporting · 29 Oct 2026
Original financial-news report read; annual guidance and accounting impact matched against Reuters.
- Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Reuters · Reporting · 29 Oct 2026
Deena Beasley’s report includes an interview with the company’s chief commercialization officer. Reuters and RTTNews are separate reporting organisations.